These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22205303)

  • 41. Compound Astragalus and Salvia miltiorrhiza extract inhibits cell proliferation, invasion and collagen synthesis in keloid fibroblasts by mediating transforming growth factor-β / Smad pathway.
    He S; Yang Y; Liu X; Huang W; Zhang X; Yang S; Zhang X
    Br J Dermatol; 2012 Mar; 166(3):564-74. PubMed ID: 21967214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protection against TGF-β1-induced fibrosis effects of IL-10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring.
    Shi JH; Guan H; Shi S; Cai WX; Bai XZ; Hu XL; Fang XB; Liu JQ; Tao K; Zhu XX; Tang CW; Hu DH
    Arch Dermatol Res; 2013 May; 305(4):341-52. PubMed ID: 23321694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elevated collagen synthesis in cultured keloid fibroblasts.
    Cohen IK; Diegelmann RF; McCoy B
    Surg Forum; 1977; 28():526-7. PubMed ID: 617527
    [No Abstract]   [Full Text] [Related]  

  • 44. Suppression of TGF-β1/SMAD pathway and extracellular matrix production in primary keloid fibroblasts by curcuminoids: its potential therapeutic use in the chemoprevention of keloid.
    Hsu YC; Chen MJ; Yu YM; Ko SY; Chang CC
    Arch Dermatol Res; 2010 Dec; 302(10):717-24. PubMed ID: 20717830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis.
    Amadeu T; Braune A; Mandarim-de-Lacerda C; Porto LC; Desmoulière A; Costa A
    Pathol Res Pract; 2003; 199(7):469-73. PubMed ID: 14521263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 3D modeling of keloid scars in vitro by cell and tissue engineering.
    Suttho D; Mankhetkorn S; Binda D; Pazart L; Humbert P; Rolin G
    Arch Dermatol Res; 2017 Jan; 309(1):55-62. PubMed ID: 27942931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. mTOR as a potential therapeutic target for treatment of keloids and excessive scars.
    Ong CT; Khoo YT; Mukhopadhyay A; Do DV; Lim IJ; Aalami O; Phan TT
    Exp Dermatol; 2007 May; 16(5):394-404. PubMed ID: 17437482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistochemical evaluation of COX-1 and COX-2 expression in keloid and hypertrophic scar.
    Abdou AG; Maraee AH; Saif HF
    Am J Dermatopathol; 2014 Apr; 36(4):311-7. PubMed ID: 24061401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Contractility, transforming growth factor-beta, and plasmin in fetal skin fibroblasts: role in scarless wound healing.
    Coleman C; Tuan TL; Buckley S; Anderson KD; Warburton D
    Pediatr Res; 1998 Mar; 43(3):403-9. PubMed ID: 9505281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The systematic effects of chitosan on fibroblasts derived from hypertrophic scars and keloids.
    Lv C; Dai H; Xing X; Zhang J
    Indian J Dermatol Venereol Leprol; 2012; 78(4):520. PubMed ID: 22772638
    [No Abstract]   [Full Text] [Related]  

  • 51. Topical tamoxifen therapy in hypertrophic scars or keloids in burns.
    Gragnani A; Warde M; Furtado F; Ferreira LM
    Arch Dermatol Res; 2010 Jan; 302(1):1-4. PubMed ID: 19636578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Course of the wound process following the cryodestructon of hypertrophic and keloid scars].
    Lositskaia VM; Bur'ianov AA
    Klin Khir (1962); 1987; (3):11-2. PubMed ID: 3573614
    [No Abstract]   [Full Text] [Related]  

  • 53. The molecular basis of keloid and hypertrophic scar formation.
    Tuan TL; Nichter LS
    Mol Med Today; 1998 Jan; 4(1):19-24. PubMed ID: 9494966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Signaling networks in barrier homeostasis. The mystery widens.
    Elias PM; Ansel JC; Woods LD; Feingold KR
    Arch Dermatol; 1996 Dec; 132(12):1505-6. PubMed ID: 8961883
    [No Abstract]   [Full Text] [Related]  

  • 55. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis.
    Verhaegen PD; van Zuijlen PP; Pennings NM; van Marle J; Niessen FB; van der Horst CM; Middelkoop E
    Wound Repair Regen; 2009; 17(5):649-56. PubMed ID: 19769718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overview about the keloid scars and the elaboration of a non-invasive, unconventional treatment.
    Carantino I; Florescu IP; Carantino A
    J Med Life; 2010; 3(2):122-7. PubMed ID: 20968196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of pathological scarring: role of myofibroblasts and current developments.
    Sarrazy V; Billet F; Micallef L; Coulomb B; Desmoulière A
    Wound Repair Regen; 2011 Sep; 19 Suppl 1():s10-5. PubMed ID: 21793960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration.
    Fujiwara M; Muragaki Y; Ooshima A
    Br J Dermatol; 2005 Aug; 153(2):295-300. PubMed ID: 16086739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of TIMP-1 and HSP47 synthesis in primary keloid fibroblasts by exogenous nitric oxide.
    Hsu YC; Wang LF; Chien YW; Lee WR
    J Dermatol Sci; 2007 Jan; 45(1):37-44. PubMed ID: 17145168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion.
    Ong CT; Khoo YT; Tan EK; Mukhopadhyay A; Do DV; Han HC; Lim IJ; Phan TT
    J Pathol; 2007 Jan; 211(1):95-108. PubMed ID: 17136757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.